Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion